Shionogi
Clinical trials sponsored by Shionogi, explained in plain language.
A Japanese pharmaceutical company focused on infectious diseases and pain management.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Hope for rare brain disorder: new drug trial targets Jordan's syndrome
Disease control OngoingThis study tests a drug called zatolmilast in 30 people aged 9 to 45 with Jordan's Syndrome, a rare genetic disorder affecting brain development. The goal is to see if the drug improves language and communication skills and is safe. Participants take the drug or a placebo for 24 …
Phase: PHASE2 • Sponsor: Shionogi • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug combo targets breathing pauses in sleep apnea
Symptom relief OngoingThis Phase 2A study tests three drugs—sivopixant, acetazolamide, and SASS-001—in 60 adults with sleep apnea that has a central component (where the brain fails to signal breathing). The goal is to see if these drugs can reduce the number of breathing pauses during sleep. Particip…
Phase: PHASE2 • Sponsor: Shionogi • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC